P.O. Witteveen

Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer

Maite Timmermans, Maaike A. van der Aa, Roy Lalisang et al. · Gynecologic Oncology · 2018 · 80 citations · Full text

Medicine, Oncology, Surgery +15

Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152

Jan H.M. Schellens, David S. Boss, P.O. Witteveen et al. · Journal of Clinical Oncology · 2006 · 51 citations

Medicine, Oncology, Pharmacology +15

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer

Martine Piccart, P.F. Bruning, J. Wildiers et al. · Annals of Oncology · 1995 · 32 citations

Medicine, Oncology, Pharmacology +17

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

I. E. L. M. Kuppens, P.O. Witteveen, Margaret Schot et al. · Investigational New Drugs · 2006 · 29 citations

Medicine, Pharmacokinetics, Pharmacology +14

Phase I clinical evaluation of AZD2171 in combination with gefitinib, in patients with advanced tumors

Hester van Cruijsen, Emile E. Voest, Carla M.L. van Herpen et al. · Journal of Clinical Oncology · 2005 · 26 citations

Pharmacy, Pharmacology, Pharmacotherapy +15